Efficacy of a Pseudomonas aeruginosa Serogroup O9 Vaccine.

ABSTRACT: There are currently no approved vaccines against the opportunistic pathogen Pseudomonas aeruginosa. Among vaccine targets, the lipopolysaccharide (LPS) O antigen of P. aeruginosa is the most immunodominant protective candidate. There are twenty different O antigens composed of different repeat sugars structures conferring serogroup specificity, and ten are found most frequently in infection. Thus, one approach to combat infection by P. aeruginosa could be to generate immunity with a vaccine cocktail that includes all these serogroups. Serogroup O9 is one of the ten serogroups commonly found in infection, but it has never been developed into a vaccine, likely due, in part, to the acid labile nature of the O9 polysaccharide. Our laboratory has previously shown that intra

SUBMITTER: Moustafa DA 

PROVIDER: S-EPMC10369961 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature